Jump to main content.


Glufosinate-ammonium (CASRN 77182-82-2)

IRIS
List of IRIS Substances




view QuickView

Main Contents

Go

0247

Glufosinate-ammonium; CASRN 77182-82-2

Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data, as outlined in the IRIS assessment development process. Sections I (Health Hazard Assessments for Noncarcinogenic Effects) and II (Carcinogenicity Assessment for Lifetime Exposure) present the conclusions that were reached during the assessment development process. Supporting information and explanations of the methods used to derive the values given in IRIS are provided in the guidance documents located on the IRIS website.

STATUS OF DATA FOR Glufosinate-ammonium

File First On-Line 09/30/1987

Category (section)
Status
Last Revised
Oral RfD Assessment (I.A.) on-line 05/01/1992
Inhalation RfC Assessment (I.B.) no data
Carcinogenicity Assessment (II.) no data

_I.  Chronic Health Hazard Assessments for Noncarcinogenic Effects

_I.A. Reference Dose for Chronic Oral Exposure (RfD)

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866
Last Revised — 05/01/1992

The oral Reference Dose (RfD) is based on the assumption that thresholds exist for certain toxic effects such as cellular necrosis. It is expressed in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. Please refer to the Background Document for an elaboration of these concepts. RfDs can also be derived for the noncarcinogenic health effects of substances that are also carcinogens. Therefore, it is essential to refer to other sources of information concerning the carcinogenicity of this substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file.

NOTE: The Oral RfD for glufosinate-ammonium may change in the near future pending the outcome of a further review now being conducted by the RfD/RfC Work Group.

__I.A.1. Oral RfD Summary

Critical Effect
Experimental Doses*
UF
MF
RfD

Increased absolute
and relative kidney
weights in males

13-Week Rat Feeding
Study

Hoescht AG, 1982a

NOEL: 8 ppm diet
(0.4 mg/kg/day)

LEL: 64 ppm diet
(3.2 mg/kg/day)

1000
1
4E-4
mg/kg/day

*Conversion Factors -- 1 ppm = 0.05 mg/kg/day (assumed rat food consumption)

__I.A.2. Principal and Supporting Studies (Oral RfD)

Hoescht AG. 1982a. MRID No. 00142443. Available from EPA. Write to FOI, EPA, Washington, DC 20460.

Twenty rats/sex/dose were fed diets containing 0, 8, 64, 500 or 4000 ppm of HOE 39866 (monoammonium 2-amino-4-[hydroxymethylphosphinyl]butanoate) for 13 weeks. An additional 10 rats/sex/dose were similarly treated, but were allowed a 4-week recovery period. An increase in absolute and relative kidney weights was noted in males treated with 64 ppm and above.

__I.A.3. Uncertainty and Modifying Factors (Oral RfD)

UF — An uncertainty factor of 100 was used to account for intra- and interspecies differences in sensitivity. An additional factor of 10 was used because the study was only of 90 days duration.

MF — None

__I.A.4. Additional Studies/Comments (Oral RfD)

The 90-day feeding study using dogs (NOEL = 16 ppm, equivalent to 0.4 mg/kg/day) is considered as co-principal.

Data Considered for Establishing the RfD:

1) 13-Week Feeding - rat: Principal study - see previous description; core grade minimum

2) 90-Day Feeding - dog: NOEL=16 ppm (0.4 mg/kg/day); LEL=64 ppm (1.6 mg/kg/day) (decreased weight gain, decreased absolute and relative thyroid weights in females); core grade minimum (Hoechst AG, 1982b)

3) Teratology - rat: Developmental NOEL=2.24 mg/kg/day; LEL=10 mg/kg/day (dilated renal pelvis and hydroureter); Maternal NOEL=2.24 mg/kg/day; LEL=10 mg/kg/day (hyperactivity); core grade minimum (Hoechst AG, 1985a)

4) Teratology - rat: Developmental NOEL = none; LEL=10 mg/kg/day (dilated renal pelvis and hydroureter); Maternal NOEL=none; LEL=10 mg/kg/day (hyperactivity); core grade supplementary (Hoechst AG, 1985b)

Data Gap(s): Chronic Dog Feeding Study; Chronic Rat Feeding Study; Rat Reproduction Study; Rabbit Teratology Study

__I.A.5. Confidence in the Oral RfD

Study — High
Database — Medium
RfD — Medium

The principal study is of good quality and is given a high confidence rating. Since the database on chronic toxicity and reproduction is incomplete, confidence in the database can be considered medium to low. Confidence in the RfD can also be considered medium to low.

__I.A.6. EPA Documentation and Review of the Oral RfD

Source Document — This assessment is not presented in any existing U.S. EPA document.

Other EPA Documentation — Pesticide Registration files

Agency Work Group Review — 02/18/1987

Verification Date — 02/18/1987

Screening-Level Literature Review Findings — A screening-level review conducted by an EPA contractor of the more recent toxicology literature pertinent to the RfD for Glufosinate-ammonium conducted in November 2001 identified one or more significant new studies. IRIS users may request the references for those studies from the IRIS Hotline at hotline.iris@epa.gov or (202)566-1676.

__I.A.7. EPA Contacts (Oral RfD)

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202)566-1676 (phone), (202)566-1749 (FAX) or hotline.iris@epa.gov (internet address).

Top of page


_I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866

Not available at this time.

Top of page


_II.  Carcinogenicity Assessment for Lifetime Exposure

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866

This substance/agent has not undergone a complete evaluation and determination under US EPA's IRIS program for evidence of human carcinogenic potential.

Top of page


_III.  [reserved]
_IV.  [reserved]
_V.  [reserved]


_VI.  Bibliography

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866
Last Revised — 09/01/1990

_VI.A. Oral RfD References

Hoescht AG. 1982a. MRID No. 00142443. Available from EPA. Write to FOI, EPA, Washington, DC 20460.

Hoescht AG. 1982b. MRID No. 00149239. Available from EPA. Write to FOI, EPA, Washington, DC 20460.

Hoescht AG. 1985a. MRID No. 00151499. Available from EPA. Write to FOI, EPA, Washington, DC 20460.

Hoescht AG. 1985b. MRID No. 00151500. Available from EPA. Write to FOI, EPA, Washington, DC 20460.

Top of page


_VI.B. Inhalation RfD References

None

Top of page


_VI.C. Carcinogenicity Assessment References

None

Top of page


_VII.  Revision History

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866

Date
Section
Description
09/01/1990 I.A. Principal study citation year corrected
09/01/1990 I.A.4. Citations added
09/01/1990 VI. Bibliography on-line
05/01/1992 I.A. Oral RfD summary noted as pending change
08/01/1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
12/03/2002 I.A.6. Screening-Level Literature Review Findings message has been added.

Top of page


_VIII.  Synonyms

Substance Name — Glufosinate-ammonium
CASRN — 77182-82-2
Primary Synonym — Hoe 39866
Last Revised — 09/30/1987

Top of page

Recent Additions | Search IRIS | IRIS Home | NCEA Home | ORD Home


Jump to main content.